Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Novo has seen Eli Lilly’s rival drug Zepbound overtake it in terms of prescriptions in the key U.S. market this year. With Wegovy, Novo was first-to-market with a highly effective obesity treatment, ...

The amount of credits the company receives is contingent upon its meeting job creation and capital investment goals.